Insider · CIK 0002071581
Suma Gopinathan
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing -, latest -.
Suma Gopinathan files SEC Form 4 as officer at LXRX (LEXICON PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Suma Gopinathan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +14,000 | - | - | 88,520 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +20,310 | - | - | 108,830 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +65,640 | - | - | 174,470 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -24,338 | $1.47 | $36k | 150,132 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -14,000 | - | - | 0 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -20,310 | - | - | 20,310 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -65,640 | - | - | 131,280 | Mar 3, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +238,450 | $0.00 | $0 | 238,450 | Feb 17, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +357,680 | $0.00 | $0 | 357,680 | Feb 17, 2026 |
Questions about Suma Gopinathan
Answered from the filings on this page, as of the latest one.
Is Suma Gopinathan buying or selling?
Suma Gopinathan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Suma Gopinathan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Suma Gopinathan has 0.
Where does Suma Gopinathan file Form 4?
Suma Gopinathan has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.) as SVP, Discovery. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.